All News
Equivalent Healthcare Outcomes by Nurses and Physicians
With increasing demand for health services in an aging population, serving complex patients with comorbidities, and increasing healthcare costs, the question of whether nurses can substitute for physicians was addressed by a recent Cochrane review.
Supportive vs Flexible Footwear in Hip Osteoarthritis
Do shoes make a difference in osteoarthritis (OA)? Common advice often suggests that stable supportive shoes can improve arthritis symptoms in the knee, but does this apply to hip osteoarthritis?
Read Article
FDA has approved tocilizumab-anoh (Avtozma; Celltrion), a biosimilar to Actemra, for intravenous and subcutaneous use in rheumatoid arthritis (RA), giant cell arteritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, and COVID-19. https://t.co/qw7SJ7ZCK9
Dr. John Cush RheumNow ( View Tweet)
Taiwan National retrospective study (2001-20) of 8732 newly Dx, biologic-naïve RA pts initiating b/tsDMARDs. Found no difference in malignancy event rates between DMARDs. 2.16% over 5-yr & 2.89% over 18yrs. (6384 Rx w/ TNFis, 667 w/ TCZ, 656 w/ ABA, 1025 on tsDMARDs) https://t.co/54ZMPywEYI
Dr. John Cush RheumNow ( View Tweet)
Should I become a physician or physician assistant/associate? Practical overview from US News. KEY QUESTIONS: 1) which is harder to get into? 2) Career flexibility? 3) Work-Life balance? 4) Which fits for you? Both are a lifelong commitment to patient care. https://t.co/szv1nUmkYQ
Dr. John Cush RheumNow ( View Tweet)
Is Giant cell arteritis over diagnosed or over-referred? Caution IF the patient is: 1) under age 50yrs; 2) has Hx of chronic HA or migraine; 3) has normal ESR/CRP. Why not consider screen w/ Giant Cell Arteritis Probability Score (needing 9.5/32 points) https://t.co/qnCWgzjYJ4 https://t.co/LT6atm0m8f
Links:
Dr. John Cush RheumNow ( View Tweet)
UK Retrospective analysis of 2 RA cohorts, 2,701 pts (F/U 6 yrs) = 101 (3.7%) Dx with ILD. (12 @ baseline, 46 w/ F/U, 43 @ death). ILD Dx signif. assoc w/ onset age (aOR 1.03), seropositivity (aOR 2.58), ever smoking (aOR 1.7). https://t.co/Zvkb1Wjpa4 https://t.co/YMkWDc3rMr
Dr. John Cush RheumNow ( View Tweet)
Danish DERMBIO registry of psoriasis pts Rx w/ biologics. Among 3790 bionaive pts ustekinumab had best 1-5 yr survival vs (ADA & SEC). In 3403 bioexperienced pts, bimekizumab, guselkumab, & risankizumab had highest 2-year drug survival rate. https://t.co/TInyLPMYkb https://t.co/UTPqa9erPU
Dr. John Cush RheumNow ( View Tweet)
AMA survey of 502 nurse practitioners (95% work on a MD-led team - 88% were satisfied; Half very satisfied working w/ MDs. 94% valued physician mentorship; 89% cited patient safety as a key benefit to physician-led care; and 88% listed liability protection as a key benefit. https://t.co/SVvr3XEQSz
Dr. John Cush RheumNow ( View Tweet)
American College of Chest Physicians has announced that advanced practice providers (APPs) can earn the CHEST Critical Care Advanced Practice Provider (CCAPP) designation; CCAPP Certification exam designed to validate clinical competence & Enhanced credibility/recognition https://t.co/Ip6YMjwOBc
Dr. John Cush RheumNow ( View Tweet)
FDA Commissioner Marty Makary is seeking to make more drugs available without a prescription; and has stated “everything should be over-the-counter” unless the drug is addictive, unsafe, or requires monitoring. https://t.co/CGurlOWO8m https://t.co/bFwkpZ3kbn
Dr. John Cush RheumNow ( View Tweet)
Full read review of JAK inhibitors. JAK inhibitors have a reasonably rapid onset of action and a short half-life, which facilitates management of any adverse effects. The half-life of Tofacitinib, Baricitinib & Upadacitinib is 3 hrs, 13 hrs. & 9-14hrs. https://t.co/jKO2LL2TVC
Dr. John Cush RheumNow ( View Tweet)
Epidemiology of Dry Eye Autoimmune Disease
Rates upwards of 20% were seen across nine common autoimmune diseases other than Sjögren's, most often in rheumatoid arthritis (39.3%) with Crohn's disease bringing up the rear (23.0%), according to Chi-Chin Sun, MD, PhD, of Chang Gung https://t.co/lnacSUlrI8
Dr. John Cush RheumNow ( View Tweet)
Congratulations to Dr. Kevin Tracey for being named toTIME100 2026 Health list. He is president & CEO of the Feinstein Institutes for Medical Research and helped develop vagal N. Stimulation in RA from SetPoint https://t.co/rgtVUldNLt https://t.co/Y4ka9GSORx
Links:
Dr. John Cush RheumNow ( View Tweet)
Case-control study of 72 estab. & 56 early RA pts the diagnostic performance of 14-3-3η testing showed AUC ≥0.85 for early & estab.RA. Early RA, -CCP had better specificity (96.4%) and a positive likelihood ratio (21.2%), while 14-3-3η had higher sensitivity (88.1%) https://t.co/jaUux9quy6
Dr. John Cush RheumNow ( View Tweet)
3 Months of Romosozumab in Postmenopausal Osteoporosis
A report in The Lancet Diabetes & Endocrinology suggested that 3 months of romosozumab (ROMO) followed by denosumab is as effective at increasing hip bone mineral density (BMD) as the standard 12-month course. https://t.co/6HfGFZqavF
Dr. John Cush RheumNow ( View Tweet)
July 2024 survey of 143 women (18-45 yrs) with rheumatic disease shows only 63% used effective contraception. In those previously pregnant, 33% experienced an unplanned pregnancy, highlighting contraceptive failure. https://t.co/tR6976vmJp https://t.co/1XRkQfWL5r
Dr. John Cush RheumNow ( View Tweet)
Sonelokimab (SLK) is a nanobody that inhibits IL-17A & IL-17F. Press release from Moonlake shows SLK was effective in the phase 2, S-OLARIS study of 26 axial spondyloarthritis pts where 80+% of patients achieved ASAS40 by Week 12 https://t.co/BQjBcvESfe https://t.co/tXRKj8CPbz
Dr. John Cush RheumNow ( View Tweet)
Nice simple overview of SCLERITIS. https://t.co/ndnfi6nZuA https://t.co/bzkOgupk7C
Links:
Dr. John Cush RheumNow ( View Tweet)
Real-world study of 1202 #PsA pts shows that secukinumab retention rates were lower w/ smoking (79%/73%/72% in never/former/current smokers) but not w/ obesity (72%/77%/77% in normal/overweight/obese), Adh HR signif. higher w/ former (1.32) & current smokers (1.27) https://t.co/1REWmod73W
Dr. John Cush RheumNow ( View Tweet)
